Showing results (161-170 of 785) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|December 5, 2025
Strengthening nationally led approaches to new product introduction for HIV preventionHasina Subedar, Nondumiso B Q Ncube, Herbert Kadama, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
The Lancet. HIV|January 9, 2025
Event-driven PrEP beyond cisgender men who have sex with menWhitney C Irie, Melanie R Nicol, Meredith Clement, et al.
The Lancet. HIV|December 16, 2024
Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trialJennifer Velloza, Nicole Poovan, Allison Meisner, et al.
The Lancet. HIV|February 6, 2025
Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort studyCheryl Hendrickson, Kamban Hirasen, Constance Mongwenyana, et al.
The Lancet. HIV|December 13, 2024
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact AssessmentsMansoor Farahani, Shannon M Farley, Theodore F Smart, et al.
The Lancet. HIV|January 6, 2025
Target product profile for cell-based and gene-based therapies to achieve a cure for HIVSharon R Lewin, Cathy Bansbach, Dominic Kemps, et al.
The Lancet. HIV|December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept studyDeborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
The Lancet. HIV|December 23, 2023
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Jean-Michel Molina, Pedro Cahn, et al.
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
Pageof 79